Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors

키워드

참고문헌 (21)

1. Li C, "The pathogenesis and treatment of chronic allograft nephropathy", Nat Rev Nephrol, 5, pp.513~519 (2009)
2. Kasiske BL, "Cancer after kidney transplantation in the United States", Am J Transplant, 4, pp.905~913 (2004)
3. Vincenti F, "Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus", Am J Transplant, 7, pp.1506~1514 (2007)
4. Stallone G, "Sirolimus for Kaposi’s sarcoma in renal-transplant recipients", N Engl J Med, 352, pp.1317~1323 (2005)
5. Saemann MD, "The multifunctional role of mTOR in innate immunity: implications for transplant immunity", Am J Transplant, 9, pp.2655~2661 (2009)
6. Zhao T, "Comparison of regulatory T cells and FoxP3-positive T-cell subsets in the peripheral blood of renal transplant recipients with sirolimus versus cyclosporine: a preliminary study", Transplant Proc, 45, pp.148~152 (2013)
7. Stallone G, "Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients", J Am Soc Nephrol, 16, pp.3755~3762 (2005)
8. Schena FP, "Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial", Transplantation, 87, pp.233~242 (2009)
9. Weir MR, "Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial", Kidney Int, 79, pp.897~907 (2011)
10. Guba M, "Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation", Transpl Int, 25, pp.416~423 (2012)
11. Soleimani AR, "Comparison of cyclosporine and sirolimus effects on serum creatinine level over five years after kidney transplantation", Transplant Proc, 45, pp.1644~1647 (2013)
12. Diekmann F, "Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy:benefits and risks", Nephrol Dial Transplant, 21, pp.562~568 (2006)
13. Alvarez-Lara MA, "The imbalance in the ratio of Th1 and Th2 helper lymphocytes in uraemia is mediated by an increased apoptosis of Th1subset", Nephrol Dial Transplant, 19, pp.3084~3090 (2004)
14. Lebranchu Y, "Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study", Am J Transplant, 9, pp.1115~1123 (2009)
15. Guba M, "Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial", Transplantation, 90, pp.175~183 (2010)
16. Li Y, "CNI induced Th17", Treg imbalance and susceptibility to renal dysfunction in renal transplantation, 2011, pp.11, 2033~2038
17. Chung BH, "Dysregulation of Th17 cells during the early post-transplant period in patients under calcineurin inhibitor based immunosuppression", PLoS One, 7, pp.e42011~ (2012)
18. Kim KW, "The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients", Immunology, 144, pp.68~78 (2015)
19. Yap M, "Expansion of highly differentiated cytotoxic terminally differentiated effector memory CD8+ T cells in a subset of clinically stable kid-ney transplant recipients: a potential marker for late graft dysfunction", J Am Soc Nephrol, 25, pp.1856~1868 (2014)
20. Pallet N, "Adverse events associated with mTOR inhibitors", Expert Opin Drug Saf, 12, pp.177~186 (2013)
21. Chuang P, "Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus", Am J Transplant, 7, pp.714~717 (2007)

관련 논문AI추천